PartnershipJun 30, 2026, 04:37 PM
Tenax Secures Supply Agreement & Extends License Deadline with Orion
AI Summary
TENAX THERAPEUTICS, INC. has entered into a Supply Agreement with Orion Corporation, making Orion the primary supplier of orally administered levosimendan product. The agreement has an initial term of five years with automatic three-year renewals and includes cost-sharing for manufacturing scale-up. Concurrently, Tenax and Orion signed the Sixth Amendment to their License Agreement, extending the regulatory approval milestone date for the product in the United States to December 31, 2035, and adding cybersecurity compliance requirements for Tenax.
Key Highlights
- Entered into a Supply Agreement with Orion Corporation for orally administered levosimendan product.
- Supply Agreement has an initial term of five years from first delivery, with automatic three-year renewals.
- Supply Agreement includes cost-sharing for scaling up Orion's manufacturing capabilities.
- Signed Sixth Amendment to License Agreement with Orion, extending regulatory approval deadline to December 31, 2035.
- Sixth Amendment requires Tenax to comply with Orion's information and cybersecurity requirements.
Price Impact
More from TENX